4 assets in Ovarian Embryonal Carcinoma

Therapeutic assets addressing Ovarian Embryonal Carcinoma, rated under Floatz methodology v0.2 and sorted by current rating.

Asset	Sponsor	Phase	Rating
Carboplatin Ovarian Embryonal Carcinoma	Children's Oncology Group	P3	BB (66)
Bleomycin Ovarian Embryonal Carcinoma	Children's Oncology Group	P3	BB (64)
Cis-Diamminedichloroplatinum Ii Ovarian Embryonal Carcinoma	Children's Oncology Group	P3	BB (64)
Etoposide Ovarian Embryonal Carcinoma	Children's Oncology Group	P3	BB (64)